Industry Trend Analysis - Limited Rewards To Discourage Pharmaceutical Investment - JUNE 2017
BMI View : Innovative pharmaceutical firms will be faced with a myriad of challenges in Peru, ranging from weak intellectual property enforcement to a high degree of bureaucracy, limiting market access for their products. There has been no evidence to suggest an improvement in the operating environment and as such Peru will remain a highly unattractive market for patented drug launches.
The Pharmaceutical Research and Manufacturers of America (PhRMA) produces an annual submission to the United States Trade Representative (USTR) for inclusion in its Special 301 report, highlighting the challenges faced by innovative pharmaceutical firms in key international markets. While the fundamental issues facing innovative drugmakers in Peru have remained broadly similar for a number of years, the 2017 submission recommends Peru to be included on the Priority Watch List, indicating serious intellectual property rights deficiencies that require increased USTR attention. Since the first report in 2012, and up to 2016, Peru has been recommended for the lower-priority Watch List of countries. Peru is one of five Latin American countries included in this category, highlighting the high degree of market access barriers faced by innovative drugmakers within the region.
Additional Regulatory Issues
|An Unattractive Market|
|Risks & Rewards For Innovative Drugmakers In Peru|
|Source: BMI's Innovative Pharmaceuticals Risk/Reward Index|